You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Medtronic
Johnson and Johnson
Baxter
Express Scripts

Last Updated: February 18, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,872,854


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,872,854 protect, and when does it expire?

Patent 9,872,854 protects OTEZLA and is included in one NDA.

This patent has nine patent family members in nine countries.

Summary for Patent: 9,872,854
Title:Methods for the treatment of psoriatic arthritis using apremilast
Abstract: Methods of treating, managing or preventing psoriatic arthritis are disclosed. Specific methods encompass the administration of apremilast, alone or in combination with a second active agent.
Inventor(s): Day; Robert (Newtown, PA)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:14/209,874
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,872,854
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 9,872,854

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Celgene Corp OTEZLA apremilast TABLET;ORAL 205437-001 Mar 21, 2014 RX Yes No   Start Trial   Start Trial TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE   Start Trial
Celgene Corp OTEZLA apremilast TABLET;ORAL 205437-001 Mar 21, 2014 RX Yes No   Start Trial   Start Trial TREATMENT OF PSORIATIC ARTHRITIS WITH APREMILAST USING A DOSAGE TITRATION SCHEDULE AND A SECOND ACTIVE AGENT   Start Trial
Celgene Corp OTEZLA apremilast TABLET;ORAL 205437-002 Mar 21, 2014 RX Yes No   Start Trial   Start Trial TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE   Start Trial
Celgene Corp OTEZLA apremilast TABLET;ORAL 205437-002 Mar 21, 2014 RX Yes No   Start Trial   Start Trial TREATMENT OF PSORIATIC ARTHRITIS WITH APREMILAST USING A DOSAGE TITRATION SCHEDULE AND A SECOND ACTIVE AGENT   Start Trial
Celgene Corp OTEZLA apremilast TABLET;ORAL 205437-003 Mar 21, 2014 RX Yes Yes   Start Trial   Start Trial TREATMENT OF PSORIATIC ARTHRITIS WITH APREMILAST USING A DOSAGE TITRATION SCHEDULE AND A SECOND ACTIVE AGENT   Start Trial
Celgene Corp OTEZLA apremilast TABLET;ORAL 205437-003 Mar 21, 2014 RX Yes Yes   Start Trial   Start Trial TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,872,854

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014235273   Start Trial
Brazil 112015020584   Start Trial
China 105050624   Start Trial
Hong Kong 1215671   Start Trial
Israel 239499   Start Trial
South Korea 20150126618   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Mallinckrodt
Boehringer Ingelheim
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.